Establishment Labs (ESTA) Q1 2026 earnings review
U.S. Launch Drives Massive Growth, Profitability Inflecting
Establishment Labs continues to execute a textbook commercial launch in the U.S. market. Q1 revenue surged 44.7% YoY to $59.9 million, driven by U.S. Motiva sales hitting $19.6 million. The company is successfully translating this top-line hypergrowth into bottom-line progress: gross margins expanded to 70.7%, and Adjusted EBITDA remained positive for the third consecutive quarter. With the minimally invasive platform exceeding early expectations and guidance raised across the board, the company is proving it can sustainably fund its own growth without additional equity.
🐂 Bull Case
The company grew revenue by nearly 45% YoY while holding operating expense growth to just 8.9%. This structural leverage proves the business model scales highly efficiently as U.S. volume ramps.
Q1 saw $9.1 million in minimally invasive platform revenue (Mia/Preservé), prompting management to raise full-year guidance for this segment to over $35 million. This expands the total addressable market and commands a price premium.
🐻 Bear Case
While U.S. growth is accelerating, OUS revenue declined sequentially from $47.3M in 25Q4 to $40.3M in 26Q1. The company remains vulnerable to distributor order timing and varying international macro environments.
Despite positive Adjusted EBITDA, the company posted a $13.4 million net loss. A heavy debt load resulted in $7.1 million of interest expense for the quarter, pushing true bottom-line profitability further out.
⚖️ Verdict: 🟢
Bullish. The pace of U.S. market penetration is exceptional, and the demonstration of strict cost control validates the management's promise of operational leverage. The raised guidance indicates strong visibility into the rest of the year.
Key Themes
U.S. Motiva Penetration is Accelerating
The U.S. rollout remains the primary engine for the company. U.S. Motiva sales reached $19.6 million in Q1, up 13.3% sequentially from Q4 and up over 215% YoY. The U.S. now accounts for roughly 33% of total company revenue, shifting the geographic mix significantly and driving both top-line growth and gross margin expansion.
Operational Leverage Clearly Demonstrated
Management's commitment to profitable growth was fully visible in Q1. While total revenue grew 44.7% YoY, total operating expenses grew only 8.9% (to $48.8 million). This dramatic spread allowed Adjusted EBITDA to swing from a $12.1 million loss a year ago to a $1.2 million profit this quarter.
Minimally Invasive Tech Expanding the Market
The minimally invasive platform (Mia Femtech and Preservé) generated $9.1 million in Q1. Management now expects it to comprise at least 13% of total 2026 revenue (>$35 million). Because these procedures command premium pricing and attract a new demographic of women previously hesitant about traditional augmentation, this segment functions as both a margin enhancer and a market expander.
OUS Momentum Contradicts Executive Commentary
In the press release, CEO Peter Caldini stated, 'Our momentum is accelerating across both the United States and OUS markets.' However, the data shows OUS revenue actually decelerated sequentially, dropping ~15% from $47.3 million in 25Q4 to $40.3 million in 26Q1. While some of this is typical Q1 seasonality, the sequential decline in the legacy business warrants close monitoring, especially given past challenges with distributor markets like China.
Interest Burden Weighs on Net Income
Despite achieving positive Adjusted EBITDA, Establishment Labs continues to generate significant GAAP net losses ($13.4 million in Q1). The primary culprit below the operating line is interest expense, which totaled $7.1 million for the quarter. While the recent Oaktree refinancing extends maturities, the $248.6 million debt load remains a heavy anchor on true profitability.
Macroeconomic and Tariff Vulnerability
Though not explicitly updated in the Q1 print, the company manufactures entirely in Costa Rica and ships globally. Past management commentary noted that potential tariffs would have a <50 bps impact on margins, but as the U.S. becomes a dominant share of total revenue, any shifts in U.S. trade policy or global shipping dynamics represent an outsized macro risk to the company's gross margin targets.
Other KPIs
Accelerating. Up from 67.2% in the year-ago period. The company is benefiting materially from a favorable geographic mix, as the high-ASP U.S. market makes up a larger portion of total volume.
Decelerating cash burn. Cash decreased by $7.5 million during the quarter (from $75.6 million at year-end), a massive improvement compared to the $21.2 million burned in Q1 2025. This keeps them safely capitalized ahead of their target to generate positive free cash flow in H2 2026.
Stable and positive. This marks the third consecutive quarter of positive Adjusted EBITDA (following $1.2M in 25Q3 and $5.5M in 25Q4), achieving management's promise to turn the corner on operating profitability.
Guidance
Accelerating. Raised from the prior range of $264M - $266M. The $267.5M midpoint implies a robust ~26.7% YoY growth rate compared to FY25's $211.1 million.
Accelerating. Raised from previous guidance of $30 million. Reflects very strong early adoption of Preservé and Mia Femtech, cementing it as a core growth pillar.
Accelerating. Implies further margin expansion through the rest of the year as U.S. sales continue to compound and minimally invasive products ramp up.
Stable. Reinforces the operational leverage narrative. With Q1 OpEx at $48.8 million, the company plans to hold spending relatively flat (~$49M/quarter) for the remainder of the year while revenue scales.
Key Questions
OUS Sequential Deceleration
Total revenue declined sequentially from Q4 to Q1 despite U.S. growth, implying a roughly 15% drop in OUS markets. How much of this is standard Q1 seasonality versus ongoing lumpiness in distributor networks like China?
Minimally Invasive Cannibalization vs Expansion
With the minimally invasive platform expected to exceed $35 million this year, what percentage of these patients represent truly new market entrants versus cannibalization of traditional Motiva augmentation procedures?
Path to GAAP Net Income
With $7.1 million in quarterly interest expense on the Oaktree debt, Adjusted EBITDA alone isn't enough to reach GAAP profitability. What is the timeline and revenue scale required to cover the debt burden and generate positive net income?